Industry
Biotechnology
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
April 01, 2024 | 6:31 pm
Portfolio Pulse from Benzinga Insights
April 01, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
April 01, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
March 29, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
March 29, 2024 | 4:30 pm
Portfolio Pulse from Benzinga Insights
March 29, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
March 28, 2024 | 8:31 pm
Portfolio Pulse from Avi Kapoor
March 28, 2024 | 6:56 pm
Portfolio Pulse from Avi Kapoor
March 28, 2024 | 6:08 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.